Storia in 10 fonti

Akeso, Summit drug extends survival in closely watched lung cancer trial

Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an important barometer for a class of cancer immunotherapies known as "PD-1/VEGF inhibitors."

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo1 mesi fa

Akeso, Summit drug extends survival in closely watched lung cancer trial

originale

Timeline cronologica

domenica 31 maggio 2026·biopharmadive.com
Akeso, Summit drug extends survival in closely watched lung cancer trial
Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an important barometer for a class of cancer immunotherapies…
domenica 31 maggio 2026·statnews.com
Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.

Akeso, Summit drug extends survival in closely watched lung cancer trial

Confronto fonti

Akeso, Summit drug extends survival in closely watched lung cancer trial

Timeline cronologica

Akeso, Summit drug extends survival in closely watched lung cancer trial

Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

Akeso lung cancer drug cuts death risk 34% in landmark trial

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

Akeso lung cancer drug trial raises hopes in US$20b market

ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%

ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

Summit, Akeso drug reduces death by 34% in China lung cancer study. Here’s what it means

New drug a ‘promising step forward’ for hard-to-treat lung cancer

HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in…

Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy…

Newly developed drug helps extend the lives of lung cancer patients in trial

Upfront Ivonescimab Plus Chemo Bests PD-1 Inhibitor Combo in Advanced NSCLC

2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion…

Akeso lung cancer drug trial raises hopes in US$20b market

Akeso lung cancer drug cuts death risk 34% in landmark trial